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Abstract
Introduction: General acceptance of the robotic platform in pancreatic surgery is poor. 
One of the main concerns regarding this technique is that the likelihood of complications 
is greater compared to other approaches.
Material and Methods: We performed a retrospective analysis of our database on robotic 
pancreatic surgery.
Results: A total of 22 patients (12 male) underwent robotic pancreatic surgery. 6 pan-
creatoduodenectomies (PD 27.3%), 12 distal pancreatectomies (DP 54.5%), 2 tumor 
52 M.V. MARINO, J.W. MITUŚ, G. VACCARELLA, O. POTAPOV, A. MIRABELLA
enucleations (9.1%) and 2 pseudocyst-gastrostomy (9.1%) were performed. The overall 
operative time was 425 (390–620) min, the median blood loss was 150 ml (70–600). We 
observed 10/22 (45.4%) overall postoperative morbidity, with 4 grade III to V complica-
tions according to the Clavien-Dindo classifi cation system. The Clinically relevant pan-
creatic fi stula rate was 3/22 (13.6%): 2 in DP group, 1 in the PD group. The reoperation 
rate was 2/22, one in the PD group, the other in the PG group; while the readmission rate 
was 18.6%. There was no postoperative death during the 30 days post surgery.
Conclusion: Robotic pancreatic surgery seems to be safe and feasible and it is associ-
ated with an acceptable risk of complications, low estimated blood loss and low conver-
sion rate.
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Introduction
Despite the increasing frequency of robotic surgery, pancreatic surgery using this 
technique is still relatively uncommon. The fi rst robotic DP (distal pancreatec-
tomy) and PD (pancreatoduodenectomy) were described over a decade ago [1,2].
Robotic surgery is more expensive compared to laparoscopy and distant 
oncological results are unknown, but its advantage is its technical superiority 
over laparosocopic and open surgery [3,4]. The data currently available show 
positive results regarding patients who undergo robotic DP. These outcomes are 
faster recovery, a lower blood loss and conversion rate, improved negative mar-
gin resection, better lymph node yield and a higher spleen preservation rate [5,6]. 
In addition, intraoperative blood loss is lower, patients are discharged faster, the 
percentage of R0 negative resection margin is higher and the interval to the start 
time of adjuvant chemotherapy is shorter [7–10].
In this paper we analyze the data on 90-day post-operative complications 
after robotic pancreatic resections performed by a single surgeon.
Material and Methods
We analyzed our database on robotic pancreatic surgery retrospectively. All 22 
consecutive patients who underwent RAPS (Robotic Assisted Pancreatic Sur-
gery) from January 2015 to August 2017 were included in our study. The Data on 
patients described in this paper were part of a wider study of robotic pancreatic 
surgery described elsewhere [11].
Pre-operative staging included a CT-scan, Abdominal Ultrasound, upper 
endoscopy and MRI, which were carried out on all patients. 
All patients were discussed at MDT meetings during which the indication 
for surgery and type of operation (robotic vs. open) were established (Table 1). 
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Table 1. Exclusion Criteria for RAPS (Robotic Assisted Pancreatic Surgery)
Tumor size > 3 cm
Personal choice of patient
Lymph nodes metastases 
Clear vascular involvement
Previous major surgery in abdominal upper quadrant
BMI > 35 Kg/m2
ASA score > 3
No sustainability to pneumoperitoneum
Unavailability of the robotic platform
BMI: Body Mass Index; ASA: American Society of Anaesthesiologists.
During operations a careful intraoperative inspection of the pancreatic 
gland was always performed using a Robotic ultrasound probe after full exposure 
of the pancreas in order to confi rm the location of the tumor (Figure 1).
All postoperative complications occurring within 90 days of surgery were 
recorded prospectively and classifi ed according to the Clavien-Dindo classifi ca-
tion system [12]. Postoperative pancreatic fi stulae and delayed gastric empty-
ing were defi ned following the classifi cation proposed by the International Study 
Group of Pancreatic Fistula and Pancreatic Surgery (ISGPF–ISGPS) [13,14]. 
The resection margin was considered positive (R1) after the tumor had 
been confi rmed within 1 mm of each of the six margins of resection examined, as 
suggested by a standardized protocol [15].
The pancreatic transection was performed using an Ultrasound Dissector 
or EndoWrist Monopolar Scissors (Figure 2).
Results
A total of 22 patients underwent RAPS in our Tertiary Care Center during the 
study period. Table 2 presents the basic characteristic of these patients. 
6 pancreatoduodenectomies (PD 27.3%), 12 distal pancreatectomies (DP 
54.5%) (9 with splenectomy), 2 tumor enucleations (9.1%) and 2 Pseudocyst-
gastrostomy (9.1%) were performed. 
According to the pathology report 13 resected tumors were malignant and 
9 benign. There were 7 ductal adenocarcinomas, 3 cases of chronic pancreatitis, 
3 neuroendocrine tumors (including 1 cancer), 2 pancreatic mucinous cystoad-
enomas, 1 cystoadenocarcinoma, intraductal papillary mucinous neoplasia in 2 
cases, 1 periampullary carcinomas, 1 cholangiocarcinoma of the distal common 
bile duct and 2 pancreatic pseudocysts.
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Fig. 1. Gastroduodenal artery dissection
Fig. 2. Uncinate Process dissection
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Table 2. Demographic Aspects and Procedures 
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BMI: Body Mass Index; ASA: American Society of Anaesthesiologists; PD: Pancreaticoduodenectomy; 
DP: Distal Pancreatectomy.
The overall operative time was 425 (390–620) min, 260 (190–315) min for 
DP and 540 (480–620) min for PD, 160 (70–275) min for enucleation and 585 
(482–655) for Total Pancreatectomy (TP), while for pseudocyst-gastrostomy the 
operative time was 130 (90–210) min. The median operative time for the fi rst 
eight PD procedures was 590 min and 530 min for the last six.
Conversion to open surgery was performed in 2/22 (9.1%) patients: 1 in 
DP and 1 in the PD group. The reasons for conversion were portal or superior 
mesenteric vein involvement with failure to progress during a PD, and a severe 
pancreatitis with massive disruption of the pancreatic parenchyma which caused 
a major bleeding from the splenic artery during DP.
The median blood loss was 170 ml (80–700 ml) in the PD group, 100 ml 
(20–230 ml) in DP group and less than 30 ml (10–150 ml) in enucleation group. 
Only one patient required intraoperative blood transfusion (the threshold for 
transfusion was hemoglobin level < 6.5 mg/dl).
In 10 patients (45.4%) we observed postoperative complications (11 ad-
verse events in general), 4 of them classifi ed as serious (III to V) according to the 
Clavien-Dindo scale (table 3).
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P/G: Pseudocyst Gastrostomy; IPMN: Intraductal Papillary Mucinous Neoplasm; CBD: Common bile duct; 
GIST: Gastrointestinal Stromal Tumor.
The class I complications were 2 cases of Grade A pancreatic fi stula spon-
taneously solved, one case of grade A delayed gastric emptying and one of jejunal 
paralytic occlusion, both treated with an antiemetic drug and prolonged mainte-
nance of a naso-gastric tube.
The class II complications were 2 cases of Grade B pancreatic fi stula treat-
ed with Somatostatine and Total Parental Nutrition.
The class III complication was a case of abdominal collection treated by 
percutaneous drainage.
The class IV complications were 1 case of Grade C pancreatic fi stula 
and two cases of abdominal hemorrhage; these patients underwent reoperation 
and required intensive care unit management.
The only class V complication was cardiorespiratory failure resulting in 
an unplanned intensive care unit recovery. When classifying the complications 
depending on the procedures performed we noticed that 3/6 (50%) complica-
tions occurred in the PD group and 5/12 (41.7%) in the DP group, two compli-
cations occurred in the four patients who underwent enucleation or pseudocyst-
gastrostomy (50%).
Altogether, we observed 3 clinically relevant pancreatic fi stula and 2 bio-
chemical leaks.
Excluding patients who converted to open surgery, the rate of clinically-
relevant pancreatic fi stula after robotic-sewn jejuno-pancreatic anastomosis was 
1/5 (20%).
The two biochemical leaks (grade A) (all diagnosed on the 5th–6th postop-
erative day) were treated conservatively by performing a serial pancreatic func-
tion examination and abdominal ultrasound, the two cases of grade B pancreatic 
fi stula (both in the DP group) were treated by administration of a total parenteral 
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nutrition and antibiotic-therapy, fi nally a grade C pancreatic fi stula (observed in 
the PD group) required a reoperation on postoperative day 10 involving the crea-
tion of a new anastomosis. 
The reoperation rate for all patients was 2/22 (9.1%), a patient in the PD 
group and another in the pseudo-cysto gastrostomy group required a second-look 
laparotomy for the following indications:
– the former for a clinically signifi cant pancreatic fi stula associated with ret-
roperitoneal bleeding and peritonitis syndrome at postoperative day 10; 
– the latter for one intrabdominal hemorrhage from a branch of the SMA at 
postoperative day 6 after unsuccessful angiographic embolization.
All complications, except one, were identifi ed in the fi rst ten days after 
surgery and it was easier to manage the post-operative course thanks to the mini-
invasive surgical approach.
One patient who underwent reoperation for a grade C pancreatic fi stula 
manifested a post-operative cardiorespiratory failure associated to severe pneu-
monia. The patient was readmitted to the Intensive Care Unit where he was treat-
ed by mechanical ventilation before the referral to a specialized care center. 
No other complications were recorded during the 90 days following the 
operations. Tables 4, 5 and 6 describe in detail perioperative and oncological 
outcomes, as well as all recorded complications.
Table 4. Perioperative outcomes of patients who underwent PD and DP
Robotic PD Robotic DP Overall
Operative time, Median (Range) min 540 (480–620) 260 (190–315) 425 (390–620)
Conversion to open 1/6 (16.7%) 1/12 (8.3%) 2/18 (11.1%)
EBL, Median (Range) ml 170 (80–700) 100 (20–230) 150 (70–600)
Intraoperative transfusion rate 1/6 (16.7%) / 1/18 (5.6%)
Morbidity rate 3/6 (50%) 5/12 (41.7%) 8/18 (44.4%)
Reoperation rate 1/6 (16.7%) / 1/18 (5.6%)
Length of stay, Median (Range) days 13 (7–30) 8 (5–11) 10.5 (10–22)
Readmission rate 90-day 1/6 (16.7%) 2/12 (16.6%) 3/18 (16.7%)
Mortality rate 30-day / / /
Table 5. Oncological fi ndings









LN Harvested, Median (Range) 25 (18–35) 16 (12–22) 23.8 (12–45)
Tumor Size, Median (Range) mm 22 (10–29) 38 (18–59) 32 (12–59)
Recurrence at 24 months 1/6 (16.7%) 1/7 (14.3%) 2/13 (15.4%)
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Minor Complications 1/6 4/12 1/4 6/22
Clavien I
– Pancreatic Fistula Grade A
– Delayed Gastric Emptying 
Grade A












– Pancreatic Fistula Grade B  2 2 Anti-Secretive + Total Parenteral 
Nutrition + Antibiotics
Major Complications 2/6 1/12 1/4 4/22
Clavien III
– Abdominal Collection  1 1 Radiologic Intervention with 
percutaneous drainage
Clavien IV






Reoperation + Postoperative ICU 
Management
Clavien V
– CardioRespiratory failure   1*   1* /
* They occurred in the same patient.
The median hospital stay was 13 days (10–22) for all procedures. More 
precisely it was 15 in the case of patients who underwent TP, 13 days in the PD 
group (range 7–30) and 8 in the DP group (range 5–11), while in case of enuclea-
tions and pseudocysto-gastrostomy it was only 6 days [4–8]. 
We observed a clear benefi t regarding the post-operative length of stay, and 
we believe we shall obtain better results when we introduce an ERAS (enhanced 
recovery after surgery) protocol, also for patients with pancreatic cancers. 
The overall readmission rate was 3/22, 2 of them readmitted after DP, and 
1 patient who belonged to the PD group.
The reasons for readmissions were subphrenic fl uid collection which re-
quired percutaneous drainage, a postoperative pancreatic B fi stula requiring TPN 
for 12 days, and pulmonary distress syndrome.
The R0 resection rate was achieved in overall 12/13 patients (92.3%). The 
mean number of harvested nodes was 25 (18–35) for PD and 16 (range 12–22) 
for the DP group.
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The follow-up was carried out until 18 months after surgery. Of the 13 
patients with malignant tumors we saw 2 recurrences, one of the recurrences was 
distant and one was regional.
Discussion
The robotic platform has been used in all fi elds of surgery including such surpris-
ing locations as the breast [16], head and neck [17] and inguinal hernia [18]. The 
most promising results have been achieved with abdominal robotic operations, 
especially in colorectal and gastric surgery [19]. 
Robotic resection boasts a lower complication rate, lower margin positiv-
ity rate, lower wound infection rate and a shorter hospital stay [10]. The rate of 
postoperative complications after robotic resections ranges from 29% to 68% 
with 6% to 38% experiencing pancreatic fi stulae [20]. Indeed, we have seen simi-
lar numbers of pancreatic fi stulae in our material and it does not seem that the 
robotic approach increases its risk [4,21].
There is no diff erence between robotic and open PD regarding delayed 
gastric emptying as we observed in our experience, even if some studies have 
reported a higher incidence of grade-C delayed gastric emptying but a lower in-
cidence of grade A [10,22].
Blood loss during robotic PD is lower than after an open procedure (range 
100–485ml) [20]. This may be caused by the use of 3D vision and a quick swap 
between monopolar and bipolar [23]. The risk of post-operative pseudoaneurysm 
is reduced due to the possibility of performing a hand-sewn ligation of the gas-
troduodenal artery (Figure 3) [7].
The rate of conversion varies from 0% to 18% for PD (mean 7.3%) and for 
DP (6.5%), because dissection is diffi  cult and bleeding is likely [10,22,24]. The 
main reasons for the conversions were similar to our results. The overall conver-
sion rate in robotic PD surgery is lower than in laparoscopic surgery [20]. Moreo-
ver, we expect to further reduce the conversion rate as we gain experience [25].
The robotic technique allows mild dissection to be performed and as a re-
sult the spleen preservation rate is high [25,26]. Complete control of the anatomy 
using the 7 degree of freedom instruments is also possible, which allows surgeons 
to reach complex anatomic zones.
Like the data from the literature, where the median number of harvested 
lymph nodes ranged from 13 to 32 [27] we did not observe any diff erence be-
tween the number of lymph nodes harvested and R0 resections compared to the 
laparoscopic approach.
The median length of postoperative stay in the series reported ranged from 
9 to 23 days [28,29]. In our series we also observed relatively short postopera-
tive stays with a median of 13 days with a 8.3% readmission rate. The reduced 
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hospital stay in respect to the laparoscopic and open procedures may be associat-
ed with a lesser immunological response and can lead to adjuvant chemotherapy 
being begun sooner. If confi rmed, this may translate into better survival, as seen 
in other cancers [30].
We believe that a shorter hospital stay and faster start to chemotherapy 
may improve the oncologic outcome of patients, but the majority of reports are 
based on data from surgeons within their own learning curve and the impact of 
robots on oncologic outcomes requires further investigation.
Fig. 3. Pancreato-Jejunostomy
Conclusion
In conclusion, our data confi rm that the robotic platform in pancreatic surgery can 
off er some advantages in terms of reducing the wound infection rate, hospital stay 
and minimizing blood loss.
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Profi l powikłań pooperacyjnych po zabiegach robotowych 
w obrębie trzustki
Streszczenie 
Wprowadzenie: Ogólny stopień akceptacji dla stosowania chirurgii robotowej w chirurgii 
trzustki jest niski. Jedną z podstawowych barier dla wprowadzania tej techniki jest obawa 
przed większym niż w przypadku innych technik operacyjnych ryzykiem wystąpienia 
powikłań pooperacyjnych.
Materiał i metody: Przeprowadzono retrospektywną analizę danych szpitalnych dotyczą-
cych zabiegów operacyjnych trzustki z dostępu robotowego.
Wyniki: Ogółem operowano 22 chorych (w tym 12 mężczyzn) z zastosowaniem systemu 
robotowego do operacji trzustki. Wykonano 6 pankreatoduodenektomii (27,3%), 12 pan-
kreatektomii obwodowych (54,5%), 2 wyłuszczenia guza (9,1%) oraz 2 zespolenia pseu-
dotorbieli trzustki ze światłem żołądka (9,1%). Czas operacji wyniósł średnio 425 min 
(390–620 min), a mediana utraty krwi – 150 ml (70–600 ml). Powikłania pooperacyjne 
stwierdzono u 10 z 22 chorych (45,4%) przy czym u 4 wystąpiły powikłania w stopniu 
III–V według skali Claviena-Dindo. Klinicznie istotna przetoka trzustkowa wystąpiła 
u 3 z 22 chorych (13,6%), w tym u 2 chorych po resekcji obwodowej trzustki i u 1 po 
pankreatoduodenektomii. Reoperacje były konieczne u 2 z 22 chorych: jedna po zabiegu 
pankreatoduodenektomii i jedna po zespoleniu pseudotorbieli ze światłem żołądka. Od-
setek ponownych przyjęć do szpitala wyniósł 18,6%. Nie stwierdzono zgonów w okresie 
30 dni po zabiegu operacyjnym.
Wnioski: Robotowa chirurgia trzustki wydaje się być techniką bezpieczną i wykonalną 
przy akceptowalnym ryzyku powikłań pooperacyjnych, niskiej śródoperacyjnej utracie 
krwi oraz niskim ryzyku konwersji.
Słowa kluczowe: chirurgia trzustki, chirurgia robotowa, powikłania

